Drugs / Vorolanib
Trials 13
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04747197 | Jan 2021 → May 2022 | wet macular degeneration | EyePoint Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03511222 | Sep 2018 → Aug 2019 | gastric cancer, gastroesophageal junction adenocarcinoma, hepatocellular carcinoma | Washington University School of Medicine | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT01296581 | Feb 2011 → Jan 2014 | cancer | Tyrogenex | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT06577961 | Aug 2024 → Aug 2027 expected | renal cell carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT03583086 | Jul 2018 → Feb 2024 | non-small cell lung carcinoma, small cell lung carcinoma, thymic carcinoma | Vanderbilt-Ingram Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT01784861 | May 2013 → Aug 2020 | adenocarcinoma, pancreatic neuroendocrine neoplasm | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT07386158 | Jul 2025 → Dec 2026 expected | clear cell renal carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT07047001 | Apr 2025 → Jun 2029 expected | renal cell carcinoma | Dong Wen | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06728852 | Dec 2024 → Dec 2026 expected | non-small cell lung carcinoma | Li-kun Chen | Recruiting | No outcome recorded |
| Phase 2 | NCT06523049 | Aug 2024 → Jul 2026 overdue | renal cell carcinoma | Hao Zeng | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06406673 | Oct 2023 → Aug 2024 | small cell lung carcinoma | Henan Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04373369 | Oct 2020 → Aug 2022 | small cell lung carcinoma | Washington University School of Medicine | Terminated | No outcome recorded Stop: Business |
| Phase 31 trial | ||||||
| Phase 3 | NCT07165418 | Sep 2025 → Dec 2028 expected | renal cell carcinoma | Peking University Cancer Hospital & Institute | Not yet recruiting | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-05-04 | Xcovery Holdings, Inc. | Equinox Sciences Expands Vorolanib Opthalmology Collaboration with Eyepoint Pharmaceuticals xcovery.com ↗ |
| 2018-08-04 | Betta Pharmaceuticals Co., Ltd. | 贝达药业控股子公司美国Xcovery宣布vorolanib（X-82）联合nivolumab用药临床试验患者入组 bettapharma.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | vorolanib | “EYP-1901, an intravitreal insert containing vorolanib, a pan-VEGF receptor inhibitor packaged in a bioerodible delivery technology (Durasert E™) for sustained delivery” PMID 38881599 ↗ Apr 202412“Vorolanib (X-82) is a novel, oral, multikinase vascular endothelial growth factor (VEGF) receptor/platelet-derived growth factor (PDGF) receptor inhibitor” PMID 30478190 ↗ Nov 2018 “Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study.” PMID 33738668 ↗ Mar 2021 |
| Known as | X-82 | “Vorolanib (X-82) is a novel, oral, multikinase vascular endothelial growth factor (VEGF) receptor/platelet-derived growth factor (PDGF) receptor inhibitor” PMID 30478190 ↗ Nov 20181“Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study.” PMID 33738668 ↗ Mar 2021 |
| Action | Inhibit | “vascular endothelial growth factor (VEGF) receptor/platelet-derived growth factor (PDGF) receptor inhibitor” PMID 30478190 ↗ Nov 2018 |
| Modality | Small molecule | “Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study.” PMID 33738668 ↗ Mar 2021 |
| Route | Oral | “Adult patients with advanced solid tumors received X-82 as tablets or capsules (once daily [q.d.] or b.i.d.)” PMID 30478190 ↗ Nov 2018 |